Investigate the Mechanism of Alkaloids of Sophora Flavescens for Co-Treatment of Lung Cancer and Liver Cancer
1. Department of Pharmacy and Health Management, Hebei Chemical and Pharmaceutical College, Shijiazhuang 050026, China
2. Department of Pharmaceutical Engineering, Hebei Chemical and Pharmaceutical College, Shijiazhuang 050026, China
| Abstract: | Background: Both lung cancer and liver cancer are malignant tumors worldwide. In clinical practice, co-morbidities of lung cancer and liver cancer are not uncommon. As lung cancer and liver cancer share some common pathways in their pathogenesis, the research on co-treatment drugs for the two cancers is needed to explore potential therapeutic agents. Case information: Alkaloids of Sophora flavescens contains active ingredients and exhibits antitumor activities, but its synergistic mechanism has not been elucidated. In the present study, network pharmacology was used as a powerful tool to investigate the potential mechanism of Alkaloids of Sophora flavescens in the co-treatment of lung cancer and liver cancer. Discussion: In Alkaloids of Sophora flavescens, a total of thirteen alkaloids could co-treat lung and liver cancers by acting on 223 key targets, in which five core targets were obtained in both lung cancer and liver cancer based on the network pharmacology approach. There were six alkaloids which had a greater effect on the two cancers. The biological processes involved 10 biological processes, 10 cellular components and 10 molecular functions. Conclusion: The present study revealed the potential mechanism and provided a systematical theoretical basis for clinical application of Alkaloids of Sophora flavescens in the co-treatment of lung cancer and liver cancer. |
| Keywords: | Alkaloids of Sophora Flavescens; Lung Cancer; Liver Cancer; Core Target |
| DOI: | 10.57237/j.cmrd.2025.01.002 |
View:
Downloads:
Received: 4 March 2025
Accepted: 15 April 2025
Published Online: 4 July 2025
Funding
| 1. | High-level Talent Funding Project of Hebei Province:"333 Talent Project" Talent Training Funding Project (C20221100) |
References
| [1] | Zhang JT, Liu SY, Gao W, et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer [J]. Cancer Discov, 2022, 12(7): 1690-1701. https://doi.org/10.1158/2159-8290.CD-21-1486 |
| [2] | Li Y, Wu X, Yang P, et al. Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis [J]. Genomics Proteomics Bioinformatics, 2022, 20(5): 850-866. https://doi.org/10.1016/j.gpb.2022.11.003 |
| [3] | Xu H, Zhang H, Li B, et al. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis [J]. BMC Cancer, 2024, 24(1): 1008. https://doi.org/10.1186/s12885-024-12772-y |
| [4] | Li S, Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III randomized study [J]. J Clin Oncol, 2023, 41(10): 1898-1908. https://doi.org/10.1200/JCO.22.01142 |
| [5] | Pan H, Zhou L, Cheng Z, et al. Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase trial II [J]. Nat Commun, 2024, 15(1): 9350. https://doi.org/10.1038/s41467-024-53704-5 |
| [6] | Li Z, Liu J, Zhang B, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial [J]. Nat Commun, 2024, 15(1): 3260. https://doi.org/10.1038/s41467-024-47420-3 |
| [7] | Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis [J]. Int J Mol Sci, 2021, 22(16): 8661. https://doi.org/10.3390/ijms22168661 |
| [8] | Hao L, Li S, Deng J, et al. The current status and future of PD-L1 in liver cancer [J]. Front Immunol, 2023, 14: 1323581. https://doi.org/10.3389/fimmu.2023.1323581 |
| [9] | Liu X, Chen L, Sun P, Zhan Z, Wang J. Anti-tumor Effect of Alkaloids of Chinese Medicine: A Review [J]. Chin. J. Exp. Tradit. Med. Formulae, 2023, 29: 264-272. https://doi.org/10.13422/j.cnki.syfjx.20230425 |
| [10] | Liu Y, Xu Y, Ji W, et al. Anti-tumor activities of matrine and oxymatrine: literature review [J]. Tumour Biol. 2014, 35: 5111-5119. https://doi.org/10.1007/s13277-014-1680-z |
| [11] | Chen MH, Gu YY, Zhang AL, et al. Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer [J]. Pharmacol Res. 2021, 171: 105778. https://doi.org/10.1016/j.phrs.2021.105778 |
| [12] | Yong J, Wu X, Lu C. Anticancer Advances of Matrine and Its Derivatives [J]. Curr Pharm Des. 2015; 21: 3673-3680. https://doi.org/10.2174/1381612821666150122123748 |
| [13] | Yuan C, Wang MH, Wang F, et al. Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer [J]. Life Sci. 2021, 270: 119105. https://doi.org/10.1016/j.lfs.2021.119105 |
| [14] | Gao F, Niu Y, Sun L, et al. Integrating network pharmacology and transcriptomic validation to investigate the efficacy and mechanism of Mufangji decoction preventing lung cancer [J]. J Ethnopharmacol. 2022, 298: 115573. https://doi.org/10.1016/j.jep.2022.115573 |
| [15] | Yu S, Gao W, Zeng P, et al. Exploring the effect of Gupi Xiaoji Prescription on hepatitis B virus-related liver cancer through network pharmacology and in vitro experiments [J]. Biomed Pharmacother. 2021, 139: 111612. https://doi.org/10.1016/j.biopha.2021.111612 |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us